Drugs / SR750
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06932536 | Apr → Jul 2025 | — | Shanghai SIMR Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05753033 | Feb → Sep 2023 | — | Shanghai SIMR Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05083468 | Oct 2021 → Oct 2022 | — | Shanghai SIMR Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06571448 | Sep 2024 → Jan 2026 | trigeminal neuralgia | Shanghai SIMR Biotechnology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SR750 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06571448 ↗ |
| Route | Oral | “orally administrated by single or multiple dose of SR750 tablet” NCT05083468 ↗ |